Literature DB >> 10233859

Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response.

C Rozera1, D Carlei, P L Lollini, C De Giovanni, P Musiani, E Di Carlo, F Belardelli, M Ferrantini.   

Abstract

Our group had previously shown that transfer of the mouse interferon (IFN)-alpha1 gene into the metastasizing TS/A mammary adenocarcinoma resulted in T-cell-mediated tumor rejection and development of antitumor immunity. Moreover, we had shown that the metastatic ability of TS/A tumor cells producing IFN-alpha was strongly impaired, whereas IFN-gamma expression did not influence or augmented metastasis formation by TS/A cells. In this study, we have analyzed the in vitro and in vivo behavior of various TS/A tumor cell clones isolated after the transduction with a recombinant retroviral vector carrying the mouse IFN-beta gene. We have also compared the tumorigenicity of these clones with that of TS/A cells expressing IFN-alpha1. BALB/c mice were inoculated subcutaneously with parental TS/A cells, transduction control TS/A cells, or TS/A cells producing IFN-alpha or IFN-beta. Tumor growth was evaluated by the measurement of tumor masses and analysis of survival. The features of tumor growth and rejection were examined by histological and immunohistochemical analyses. The metastatic ability of parental TS/A cells, transduction control TS/A cells, or TS/A cells producing IFN-alpha, IFN-beta, or IFN-gamma was evaluated after intravenous injection of the tumor cells into BALB/c mice by counting of the lung metastatic nodules and analysis of survival. A strong inhibition of tumorigenicity and development of tumor immunity were observed upon subcutaneous injection of syngeneic mice with TS/A tumor cells producing high amounts of IFN-beta, but not with clones expressing low levels of the cytokine, as observed for cells expressing IFN-alpha. IFN-alpha secretion by TS/A cells at the site of tumor growth induced a stronger inflammatory response as compared with IFN-beta, which appeared to be more active in the inhibition of tumor-induced angiogenesis. Notably, the metastatic ability of IFN-beta-producing TS/A cells after intravenous injection was either not affected or only slightly impaired as compared with parental TS/A tumor cells. In contrast, even cells producing low levels of IFN-alpha proved to be poorly metastatic. These findings represent the first comparison of the effectiveness of IFN-alpha versus IFN-beta produced by genetically modified cells on their tumorigenic behavior and suggest the existence of some notable differences in the capabilities of these two cytokines to induce a host antitumor reactivity in mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233859      PMCID: PMC1866568          DOI: 10.1016/s0002-9440(10)65373-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Recombinant human interferon-beta in the treatment of condylomata acuminata.

Authors:  W Dinsmore; J Jordan; C O'Mahony; J R Harris; A McMillan; K W Radcliffe; P Engrand; B W Jackson; A R Galazka; A K Abdul-Ahad; J M Illingworth
Journal:  Int J STD AIDS       Date:  1997-10       Impact factor: 1.359

2.  Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

Authors:  K Genç; D L Dona; A T Reder
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

3.  Interferon-beta downregulates expression of VLA-4 antigen and antagonizes interferon-gamma-induced expression of HLA-DQ on human peripheral blood monocytes.

Authors:  M Soilu-Hänninen; A Salmi; R Salonen
Journal:  J Neuroimmunol       Date:  1995-07       Impact factor: 3.478

4.  Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice.

Authors:  A Fabra; M Nakajima; C D Bucana; I J Fidler
Journal:  Differentiation       Date:  1992-12       Impact factor: 3.880

5.  Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon beta.

Authors:  N Kato; A Nawa; K Tamakoshi; F Kikkawa; N Suganuma; T Okamoto; S Goto; Y Tomoda; M Hamaguchi; M Nakajima
Journal:  Am J Obstet Gynecol       Date:  1995-02       Impact factor: 8.661

Review 6.  Treatment strategies for epidemic Kaposi's sarcoma.

Authors:  M D Volm; J H von Roenn
Journal:  Curr Opin Oncol       Date:  1995-09       Impact factor: 3.645

7.  Interferon-beta strong cytopathic effect on human papillomavirus type 16-immortalized HPK-IA cell line, unexpectedly not shared by interferon-alpha.

Authors:  F De Marco; F Giannoni; M L Marcante
Journal:  J Gen Virol       Date:  1995-02       Impact factor: 3.891

8.  Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.

Authors:  F Belardelli; I Gresser; C Maury; M T Maunoury
Journal:  Int J Cancer       Date:  1982-12-15       Impact factor: 7.396

9.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

10.  Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha.

Authors:  M R Rani; G R Foster; S Leung; D Leaman; G R Stark; R M Ransohoff
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

View more
  9 in total

Review 1.  Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs.

Authors:  Adriana Albini; Stefano Indraccolo; Douglas M Noonan; Ulrich Pfeffer
Journal:  Clin Exp Metastasis       Date:  2010-04-10       Impact factor: 5.150

2.  Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach.

Authors:  A Albini; C Marchisone; F Del Grosso; R Benelli; L Masiello; C Tacchetti; M Bono; M Ferrantini; C Rozera; M Truini; F Belardelli; L Santi; D M Noonan
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

3.  Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies.

Authors:  Emi A Lutz; Yash Agarwal; Noor Momin; Sarah C Cowles; Joseph R Palmeri; Ellen Duong; Vladlena Hornet; Allison Sheen; Brianna M Lax; Adrienne M Rothschilds; Darrell J Irvine; Stefani Spranger; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

Review 4.  Is scleroderma a vasculopathy?

Authors:  Jo Nadine Fleming; Richard A Nash; William M Mahoney; Stephen Mark Schwartz
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

5.  The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis.

Authors:  Hirayuki Enomoto; Lihua Tao; Ryoji Eguchi; Ayuko Sato; Masao Honda; Shuichi Kaneko; Yoshinori Iwata; Hiroki Nishikawa; Hiroyasu Imanishi; Hiroko Iijima; Tohru Tsujimura; Shuhei Nishiguchi
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

6.  Evidence for the Role of Intracellular Water Lifetime as a Tumour Biomarker Obtained by In Vivo Field-Cycling Relaxometry.

Authors:  Maria Rosaria Ruggiero; Simona Baroni; Stefania Pezzana; Gianni Ferrante; Simonetta Geninatti Crich; Silvio Aime
Journal:  Angew Chem Int Ed Engl       Date:  2018-04-14       Impact factor: 15.336

7.  Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10.

Authors:  Shingo Takano; Eiichi Ishikawa; Masahide Matsuda; Tetsuya Yamamoto; Akira Matsumura
Journal:  Int J Oncol       Date:  2014-08-25       Impact factor: 5.650

Review 8.  Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Authors:  Ruan F V Medrano; Aline Hunger; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Oncotarget       Date:  2017-07-25

Review 9.  Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.

Authors:  Carla De Giovanni; Giordano Nicoletti; Lorena Landuzzi; Arianna Palladini; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.